Tag: neuromuscular blocking drug market industry analysis

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Neurological Disorder Diagnostics Market Forecast: What Market Value Is Expected By 2030?

The global market for diagnosing neurological conditions has experienced significant expansion lately, with projections indicating continued robust growth. This market, valued at $12.61 billion in 2025, is anticipated to reach $13.54 billion by 2026, reflecting a compound annual growth rate of 7.3%. Key factors fueling this growth during the preceding period include a surge in the incidence of neurological diseases, a heightened understanding of the advantages of early detection, the broader implementation of sophisticated imaging technologies, increased investment in neurological research, and better access to diagnostic tools.

The market for diagnosing neurological disorders is poised for considerable expansion, projected to reach $17.75 billion by 2030, expanding at a compound annual growth rate of 7.0%. This upward trajectory during the forecast period is fueled by several key factors: the increasing embrace of precision neurology, greater investment in digital diagnostic technologies, the broader implementation of individualized treatment strategies, the growing utilization of tele-neurology, and advancements in neuroinformatics and data analysis. Prominent trends anticipated within this timeframe include the wider adoption of AI-powered neuroimaging solutions, an increased demand for diagnostic kits based on biomarkers, the further integration of genetic and molecular testing into diagnostic workflows, the expansion of remote and digital options for cognitive assessments, and a heightened emphasis on the early identification of diseases.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19611&type=smp

Neurological Disorder Diagnostics Market Growth Drivers: What Factors Are Accelerating Expansion?

The escalating incidence of Alzheimer’s disease is poised to be a significant catalyst for the expansion of the market for neurological disorder diagnostics. This neurodegenerative condition is marked by a progressive deterioration of cognitive abilities, encompassing memory, logical thinking, and the capacity for problem-solving. The etiology of Alzheimer’s disease is multifactorial, involving a confluence of genetic predispositions, such as specific gene mutations and polymorphisms, the pathological aggregation of amyloid plaques and neurofibrillary (tau) tangles within the brain, persistent neuroinflammation, complications related to blood vessel health, and various lifestyle elements. Diagnostic tools for neurological disorders play a crucial role in managing Alzheimer’s disease by facilitating its early and precise identification via sophisticated imaging technologies, examination of biological markers, and thorough cognitive evaluations. Illustratively, data from the Australian Institute of Health and Welfare, a governmental body in Australia, revealed that in the year 2023, an estimated 411,100 individuals across Australia were affected by dementia, a figure comprising approximately 257,500 women and 153,700 men, as reported in September 2024. Consequently, the rising prevalence of Alzheimer’s disease serves as a primary driver for the growth trajectory of the neurological disorder diagnostics market.

Neurological Disorder Diagnostics Market Segment Breakdown: Which Categories Generate The Most Revenue?

The neurological disorder diagnostics market covered in this report is segmented –

1) By Component: Instruments, Reagents, Kits, Software, Services

2) By Technology: Immunoassay, Polymerase Chain Reaction (PCR) Techniques

3) By Disease Type: Alzheimer’s Disease, Dementia, Parkinson’s Disease, Epilepsy, Traumatic Brain Injury, Other Disease Types

4) By End User: Hospitals And Clinics, Diagnostic Centers, Academic And Research Institutes

Subsegments:

1) By Instruments: Electroencephalography (EEG) Machines, Magnetic Resonance Imaging (MRI) Machines, Computed Tomography (CT) Scanners, Positron Emission Tomography (PET) Scanners, Lumbar Puncture Equipment, Ultrasound Devices, Neurostimulation Devices, Transcranial Magnetic Stimulation (TMS) Devices,

2) By Reagents: Biochemical Reagents, Antibodies, DNA Probes, RNA Probes, Enzyme-linked Immunosorbent Assay (ELISA) Reagents, Polymerase Chain Reaction (PCR) Reagents, Sample Collection Reagents

3) By Kits: Diagnostic Test Kits, Genetic Testing Kits, Biomarker Detection Kits, Immunoassay Kits, Point-of-Care Testing Kits, Screening Kits for Neurological Disorders

4) By Software: Diagnostic Software for Imaging Analysis, Data Management Software, Clinical Decision Support Software, Patient Management Software, Laboratory Information Management Systems (LIMS), Neuroinformatics Software, Telemedicine Software

5) By Services: Diagnostic Testing Services, Consultation Services, Training and Support Services, Maintenance and Repair Services for Equipment, Telehealth Services, Data Analysis Services, Research and Development Services

Neurological Disorder Diagnostics Market Trends: What Is Shaping Future Industry Growth?

Key players within the neurological disorder diagnostics sector are concentrating their efforts on pioneering advancements, specifically in the realm of neurological disease quantification software, to address the needs of the global population of one billion individuals grappling with such conditions. This specialized software serves as a critical instrument for assessing and tracking the functional changes and the trajectory of diseases affecting the nervous system. A prime illustration of this innovation occurred in January 2024 when Quibim, a biotechnology firm headquartered in Spain, introduced its AI-driven QP-Brain software, engineered for the early detection and quantification of neurological diseases. QP-Brain represents sophisticated neuroimaging analysis technology that facilitates the measurement of brain tissue modifications associated with various neurological ailments. Its distinctive capabilities encompass AI-driven automatic segmentation processes and in-depth volumetric assessments, thereby furnishing highly accurate data on alterations in brain morphology, beneficial for both clinical practice and scientific investigation.

Neurological Disorder Diagnostics Market Key Players And Strategic Industry Positioning

Major companies operating in the neurological disorder diagnostics market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Medtronic plc, Amgen Inc., Siemens Healthineers AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Otsuka Pharmaceutical Co. Ltd., Boston Scientific Corporation, Neurocrine Biosciences Inc., Neusoft Medical Systems Co.Ltd., Nihon Kohden Corporation, Natus Medical Incorporated, Esaote S.p.A, Canon Medical Systems Corporation, NeuroPace Inc., Lifelines Neuro Company LLC, York Instruments Ltd., Advanced Brain Monitoring Inc., Neurometrix Inc., Croton Healthcare Private Limited, NeuroLogica Corporation

Access The Complete Neurological Disorder Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-diagnostics-global-market-report

Neurological Disorder Diagnostics Market Regional Analysis And Leading Geography

North Americawas the largest region in the neurological disorder diagnostics market in 2025. The regions covered in the neurological disorder diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Neurological Disorder Diagnostics Market Change Between 2026 And 2030?

The neurological disorder diagnostics market size has shown substantial growth recently. It is anticipated to increase from $12.61 billion in 2025 to $13.54 billion in 2026, registering a compound annual growth rate (CAGR) of 7.3%. This historical expansion can be linked to the rising incidence of neurological conditions, a greater understanding of the importance of early diagnosis, the expansion of sophisticated imaging infrastructure, increased funding for neurological research, and improved access to diagnostic equipment.

The neurological disorder diagnostics market size is projected for substantial expansion in the coming years. It is anticipated to reach $17.75 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.0%. This growth during the forecast period is attributable to several factors, including the increasing implementation of precision neurology approaches, growing investments in digital diagnostics platforms, the widening scope of personalized treatment planning, the expanding utilization of tele-neurology services, and progress in neuroinformatics and analytics. Key trends expected during this period involve the increasing uptake of AI-assisted neuroimaging tools, a rise in the application of biomarker-based diagnostic kits, the broadening integration of genetic and molecular testing, the expansion of remote and digital cognitive assessments, and a heightened emphasis on early disease detection.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19611&type=smp

What Influential Factors Are Boosting The Neurological Disorder Diagnostics Market Demand?

The rising occurrence of Alzheimer’s disease is anticipated to drive the expansion of the neurological disorder diagnostics market in the future. Alzheimer’s disease is defined as a progressive neurodegenerative condition marked by a slow deterioration of cognitive abilities, such as memory, reasoning, and problem-solving skills. This condition involves a combination of elements, including genetic factors like specific gene mutations and variations, the buildup of amyloid plaques and tau tangles in the brain, persistent inflammation, vascular problems, and lifestyle choices. Diagnostics for neurological disorders assist in managing Alzheimer’s by facilitating early and precise identification via sophisticated imaging methods, biomarker examinations, and cognitive evaluations. For example, reports from September 2024 by the Australian Institute of Health and Welfare, an Australia-based government entity, indicated that in 2023, approximately 411,100 individuals in Australia were living with dementia, comprising about 257,500 women and 153,700 men. Consequently, the growing incidence of Alzheimer’s disease is propelling the expansion of the neurological disorder diagnostics market.

What Are The Major Segment Categories Within The Neurological Disorder Diagnostics Market?

The neurological disorder diagnostics market covered in this report is segmented –

1) By Component: Instruments, Reagents, Kits, Software, Services

2) By Technology: Immunoassay, Polymerase Chain Reaction (PCR) Techniques

3) By Disease Type: Alzheimer’s Disease, Dementia, Parkinson’s Disease, Epilepsy, Traumatic Brain Injury, Other Disease Types

4) By End User: Hospitals And Clinics, Diagnostic Centers, Academic And Research Institutes

Subsegments:

1) By Instruments: Electroencephalography (EEG) Machines, Magnetic Resonance Imaging (MRI) Machines, Computed Tomography (CT) Scanners, Positron Emission Tomography (PET) Scanners, Lumbar Puncture Equipment, Ultrasound Devices, Neurostimulation Devices, Transcranial Magnetic Stimulation (TMS) Devices,

2) By Reagents: Biochemical Reagents, Antibodies, DNA Probes, RNA Probes, Enzyme-linked Immunosorbent Assay (ELISA) Reagents, Polymerase Chain Reaction (PCR) Reagents, Sample Collection Reagents

3) By Kits: Diagnostic Test Kits, Genetic Testing Kits, Biomarker Detection Kits, Immunoassay Kits, Point-of-Care Testing Kits, Screening Kits for Neurological Disorders

4) By Software: Diagnostic Software for Imaging Analysis, Data Management Software, Clinical Decision Support Software, Patient Management Software, Laboratory Information Management Systems (LIMS), Neuroinformatics Software, Telemedicine Software

5) By Services: Diagnostic Testing Services, Consultation Services, Training and Support Services, Maintenance and Repair Services for Equipment, Telehealth Services, Data Analysis Services, Research and Development Services

Which Trends Are Guiding The Development Of The Neurological Disorder Diagnostics Market?

Leading companies in the neurological biomarkers market are developing innovative products, including advanced biomarker blood tests, to achieve a competitive advantage. Biomarker blood tests involve the examination of specific molecules or indicators in the blood to provide data regarding a biological condition, illness, or physiological process. For example, in July 2023, Quanterix Corporation, a US-based entity focused on the development and marketing of ultra-sensitive digital immunoassay platforms, introduced the LucentAD biomarker blood test. The LucentAD test is designed to assist medical practitioners in assessing patients who exhibit cognitive symptoms consistent with early signs of Alzheimer’s disease. This test measures the levels of p-Tau 181, which has been identified as a biomarker for the pathophysiology of Alzheimer’s disease (AD). For adults being tested for AD 1 with cognitive impairment, the results of the LucentAD test are intended for use as a diagnostic tool. The test is not to be used as a standalone screening or diagnostic assay and must be utilized alongside other diagnostic instruments.

Who Are The Firms Contributing To The Neurological Disorder Diagnostics Market Ecosystem?

Major companies operating in the neurological disorder diagnostics market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Medtronic plc, Amgen Inc., Siemens Healthineers AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Otsuka Pharmaceutical Co. Ltd., Boston Scientific Corporation, Neurocrine Biosciences Inc., Neusoft Medical Systems Co.Ltd., Nihon Kohden Corporation, Natus Medical Incorporated, Esaote S.p.A, Canon Medical Systems Corporation, NeuroPace Inc., Lifelines Neuro Company LLC, York Instruments Ltd., Advanced Brain Monitoring Inc., Neurometrix Inc., Croton Healthcare Private Limited, NeuroLogica Corporation

Access The Complete Neurological Disorder Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-diagnostics-global-market-report

Which Region Commands The Largest Share Of The Neurological Disorder Diagnostics Market?

North America was the largest region in the neurological disorder diagnostics market in 2025. The regions covered in the neurological disorder diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Neurological Disorder Diagnostics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=19611&type=smp

Browse Through More Reports Similar to the Global Neurological Disorder Diagnostics Market 2026, By The Business Research Company

Central Nervous System Biomarkers Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/central-nervous-system-biomarkers-global-market-report

Clinical Biomarkers Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Biomarkers Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Neurological Disorder Diagnostics Market Between 2026 And 2030?

The neurological disorder diagnostics market has experienced robust expansion over recent years. Forecasts indicate this market will grow from $12.61 billion in 2025 to $13.54 billion in 2026, at a compound annual growth rate (CAGR) of 7.3%. The historical growth can be attributed to factors such as the increasing occurrence of neurological disorders, heightened recognition of the importance of early diagnosis, the development of sophisticated imaging infrastructure, increased funding for neurological research, and better access to diagnostic tools.

The neurological disorder diagnostics market is projected for substantial expansion in the coming years, reaching a valuation of $17.75 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.0%. This expansion during the forecast period is primarily driven by factors such as the increasing embrace of precision neurology approaches, greater investments in digital diagnostics platforms, the broadening scope of personalized treatment planning, the expanding utilization of tele-neurology services, and progress in neuroinformatics and analytics. Key trends anticipated in the same period involve a growing uptake of AI-assisted neuroimaging tools, a rise in the application of biomarker-based diagnostic kits, increased integration of genetic and molecular testing methods, the proliferation of remote and digital cognitive assessments, and a heightened emphasis on the early detection of diseases.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19611&type=smp

What Significant Factors Are Influencing The Neurological Disorder Diagnostics Market Expansion?

The escalating incidence of Alzheimer’s disease is projected to fuel the expansion of the neurological disorder diagnostics market in the coming years. Alzheimer’s disease is identified as a progressive neurodegenerative condition marked by a slow deterioration of cognitive abilities, such as memory, logical thinking, and problem-solving. Its development involves a combination of elements, including genetic predispositions like specific gene mutations and variations, the build-up of amyloid plaques and tau tangles within the brain, persistent inflammation, circulatory problems, and lifestyle choices. Neurological disorder diagnostics aid in addressing Alzheimer’s disease by facilitating timely and precise identification through sophisticated imaging methods, biomarker analysis, and cognitive evaluations. For example, in September 2024, data from the Australian Institute of Health and Welfare, an Australia-based government body, indicated that approximately 411,100 individuals in Australia were living with dementia in 2023, comprising about 257,500 women and 153,700 men. Consequently, the rising prevalence of Alzheimer’s disease is propelling the growth of the neurological disorder diagnostics market.

How Is The Neurological Disorder Diagnostics Market Organized By Segment Classification?

The neurological disorder diagnostics market covered in this report is segmented –

1) By Component: Instruments, Reagents, Kits, Software, Services

2) By Technology: Immunoassay, Polymerase Chain Reaction (PCR) Techniques

3) By Disease Type: Alzheimer’s Disease, Dementia, Parkinson’s Disease, Epilepsy, Traumatic Brain Injury, Other Disease Types

4) By End User: Hospitals And Clinics, Diagnostic Centers, Academic And Research Institutes

Subsegments:

1) By Instruments: Electroencephalography (EEG) Machines, Magnetic Resonance Imaging (MRI) Machines, Computed Tomography (CT) Scanners, Positron Emission Tomography (PET) Scanners, Lumbar Puncture Equipment, Ultrasound Devices, Neurostimulation Devices, Transcranial Magnetic Stimulation (TMS) Devices,

2) By Reagents: Biochemical Reagents, Antibodies, DNA Probes, RNA Probes, Enzyme-linked Immunosorbent Assay (ELISA) Reagents, Polymerase Chain Reaction (PCR) Reagents, Sample Collection Reagents

3) By Kits: Diagnostic Test Kits, Genetic Testing Kits, Biomarker Detection Kits, Immunoassay Kits, Point-of-Care Testing Kits, Screening Kits for Neurological Disorders

4) By Software: Diagnostic Software for Imaging Analysis, Data Management Software, Clinical Decision Support Software, Patient Management Software, Laboratory Information Management Systems (LIMS), Neuroinformatics Software, Telemedicine Software

5) By Services: Diagnostic Testing Services, Consultation Services, Training and Support Services, Maintenance and Repair Services for Equipment, Telehealth Services, Data Analysis Services, Research and Development Services

What Trends Are Affecting The Direction Of The Neurological Disorder Diagnostics Market?

Companies operating within the neurological disorder diagnostics market are primarily focused on developing innovative solutions, such as neurological disease quantification software, to address the needs of one billion individuals worldwide affected by neurological diseases. Neurological disease quantification software functions as a tool for measuring and analyzing brain function and the progression of diseases in neurological conditions. For example, in January 2024, Quibim, a biotechnology company from Spain, launched the QP-Brain, an AI-based software designed for quantifying early-stage neurological diseases. QP-Brain by Quibim is advanced neuroimaging analysis software specifically created to quantify changes in brain tissue associated with neurological diseases. Its distinguishing features include AI-powered automated segmentation and detailed volumetric analysis, providing precise insights into alterations in brain structure for both clinical and research applications.

Who Are The Industry Participants Involved In The Neurological Disorder Diagnostics Market?

Major companies operating in the neurological disorder diagnostics market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Medtronic plc, Amgen Inc., Siemens Healthineers AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Otsuka Pharmaceutical Co. Ltd., Boston Scientific Corporation, Neurocrine Biosciences Inc., Neusoft Medical Systems Co.Ltd., Nihon Kohden Corporation, Natus Medical Incorporated, Esaote S.p.A, Canon Medical Systems Corporation, NeuroPace Inc., Lifelines Neuro Company LLC, York Instruments Ltd., Advanced Brain Monitoring Inc., Neurometrix Inc., Croton Healthcare Private Limited, NeuroLogica Corporation

Get The Full Neurological Disorder Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-diagnostics-global-market-report

Which Region Is The Largest In The Neurological Disorder Diagnostics Market?

North America was the largest region in the neurological disorder diagnostics market in 2025. The regions covered in the neurological disorder diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Neurological Disorder Diagnostics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-diagnostics-global-market-report

Browse Through More Reports Similar to the Global Neurological Disorder Diagnostics Market 2026, By The Business Research Company

Central Nervous System Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/central-nervous-system-biomarkers-global-market-report

Clinical Biomarkers Market Report

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Biomarkers Market Report

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Neurological Disorder Diagnostics Market By 2030 Starting From Its 2026 Size?

The neurological disorder diagnostics market has experienced significant growth in recent years. This market is set to expand from $12.61 billion in 2025 to $13.54 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. Historically, this expansion has been propelled by factors such as the increasing prevalence of neurological disorders, a growing understanding of the importance of early diagnosis, the development of advanced imaging infrastructure, rising research funding for neurology, and enhanced availability of diagnostic instruments.

The neurological disorder diagnostics market is projected to experience substantial expansion in the coming years, reaching $17.75 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.0%. This anticipated growth during the forecast period can be linked to factors such as the increasing integration of precision neurology approaches, greater investments in digital diagnostics platforms, the broadening of personalized treatment planning, the expanding utilization of tele-neurology services, and progress in neuroinformatics and analytics. Key trends during this period are expected to encompass a wider uptake of AI-assisted neuroimaging tools, an increase in the deployment of biomarker-based diagnostic kits, greater integration of genetic and molecular testing, the spread of remote and digital cognitive assessments, and a heightened emphasis on early disease detection.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19611&type=smp

What Primary Drivers Are Shaping The Development Of The Neurological Disorder Diagnostics Market?

The rising occurrence of Alzheimer’s disease is projected to drive the expansion of the neurological disorder diagnostics market in the future. Alzheimer’s disease is defined as a progressive neurodegenerative condition marked by a slow deterioration of cognitive abilities, such as memory, reasoning, and problem-solving. Its development is linked to a combination of genetic factors, including specific gene mutations and variations, the buildup of amyloid plaques and tau tangles within the brain, persistent inflammation, vascular problems, and various lifestyle elements. Neurological disorder diagnostics aid in addressing Alzheimer’s disease by facilitating its early and precise identification via sophisticated imaging methods, biomarker analysis, and cognitive evaluations. For example, in September 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that in 2023, approximately 411,100 individuals in Australia were living with dementia, encompassing around 257,500 women and 153,700 men. Consequently, the growing prevalence of Alzheimer’s disease is fueling the expansion of the neurological disorder diagnostics market.

Which Segment Categories Define The Neurological Disorder Diagnostics Market?

The neurological disorder diagnostics market covered in this report is segmented –

1) By Component: Instruments, Reagents, Kits, Software, Services

2) By Technology: Immunoassay, Polymerase Chain Reaction (PCR) Techniques

3) By Disease Type: Alzheimer’s Disease, Dementia, Parkinson’s Disease, Epilepsy, Traumatic Brain Injury, Other Disease Types

4) By End User: Hospitals And Clinics, Diagnostic Centers, Academic And Research Institutes

Subsegments:

1) By Instruments: Electroencephalography (EEG) Machines, Magnetic Resonance Imaging (MRI) Machines, Computed Tomography (CT) Scanners, Positron Emission Tomography (PET) Scanners, Lumbar Puncture Equipment, Ultrasound Devices, Neurostimulation Devices, Transcranial Magnetic Stimulation (TMS) Devices,

2) By Reagents: Biochemical Reagents, Antibodies, DNA Probes, RNA Probes, Enzyme-linked Immunosorbent Assay (ELISA) Reagents, Polymerase Chain Reaction (PCR) Reagents, Sample Collection Reagents

3) By Kits: Diagnostic Test Kits, Genetic Testing Kits, Biomarker Detection Kits, Immunoassay Kits, Point-of-Care Testing Kits, Screening Kits for Neurological Disorders

4) By Software: Diagnostic Software for Imaging Analysis, Data Management Software, Clinical Decision Support Software, Patient Management Software, Laboratory Information Management Systems (LIMS), Neuroinformatics Software, Telemedicine Software

5) By Services: Diagnostic Testing Services, Consultation Services, Training and Support Services, Maintenance and Repair Services for Equipment, Telehealth Services, Data Analysis Services, Research and Development Services

How Are Trends Transforming The Neurological Disorder Diagnostics Market Landscape?

Companies operating within the neurological disorder diagnostics market are prioritizing the development of innovative solutions, such as neurological disease quantification software, to address the needs of one billion individuals worldwide affected by neurological diseases. Neurological disease quantification software functions as a tool for measuring and analyzing brain activity and the progression of neurological conditions. For example, in January 2024, Quibim, a Spain-based biotechnology company, launched the QP-Brain, an AI-based early-stage neurological disease quantification software. QP-Brain by Quibim is advanced neuroimaging analysis software crafted to quantify brain tissue alterations associated with neurological diseases. Its distinctive features encompass AI-powered automated segmentation and detailed volumetric analysis, delivering precise insights into brain structure changes for both clinical and research applications.

Who Are The Top Companies Competing In The Neurological Disorder Diagnostics Market?

Major companies operating in the neurological disorder diagnostics market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Medtronic plc, Amgen Inc., Siemens Healthineers AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Otsuka Pharmaceutical Co. Ltd., Boston Scientific Corporation, Neurocrine Biosciences Inc., Neusoft Medical Systems Co.Ltd., Nihon Kohden Corporation, Natus Medical Incorporated, Esaote S.p.A, Canon Medical Systems Corporation, NeuroPace Inc., Lifelines Neuro Company LLC, York Instruments Ltd., Advanced Brain Monitoring Inc., Neurometrix Inc., Croton Healthcare Private Limited, NeuroLogica Corporation

Read the full neurological disorder diagnostics market report here:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-diagnostics-global-market-report

How Does The Neurological Disorder Diagnostics Market Perform Across Major Global Regions?

North America was the largest region in the neurological disorder diagnostics market in 2025. The regions covered in the neurological disorder diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neurological Disorder Diagnostics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19611&type=smp

Browse Through More Reports Similar to the Global Neurological Disorder Diagnostics Market 2026, By The Business Research Company

Central Nervous System Biomarkers Global Market Report

https://www.thebusinessresearchcompany.com/report/central-nervous-system-biomarkers-global-market-report

Clinical Biomarkers Global Market Report

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Biomarkers Global Market Report

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the neurological disorder diagnostics market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Neurological Disorder Diagnostics Market between 2026 and 2030?

The neurological disorder diagnostics market size has experienced strong growth in recent years. It is projected to expand from $12.61 billion in 2025 to $13.54 billion in 2026, at a compound annual growth rate (CAGR) of 7.3%. This historic growth can be linked to factors such as the increasing prevalence of neurological disorders, rising awareness about the importance of early diagnosis, the expansion of advanced imaging infrastructure, growing research funding for neurology, and improved availability of diagnostic instruments.

The neurological disorder diagnostics market size is projected for substantial growth over the next few years, expected to reach $17.75 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.0%. This expansion during the forecast period is attributed to the increasing adoption of precision neurology approaches, rising investments in digital diagnostics platforms, the broadening of personalized treatment planning, the growing utilization of tele-neurology services, and advancements in neuroinformatics and analytics. Major trends anticipated in this period include the increasing integration of AI-assisted neuroimaging tools, a rising application of biomarker-based diagnostic kits, the growing integration of genetic and molecular testing, an expansion of remote and digital cognitive assessments, and an enhanced focus on early disease detection.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19611&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Neurological Disorder Diagnostics Market?

The rising occurrence of Alzheimer’s disease is anticipated to drive expansion in the neurological disorder diagnostics market in the future. Alzheimer’s disease is defined as a progressive neurodegenerative condition marked by a slow deterioration of cognitive abilities, such as memory, reasoning, and problem-solving skills. This condition results from a combination of elements like genetic factors, including specific gene mutations and variations; the buildup of amyloid plaques and tau tangles within the brain; persistent inflammation; vascular problems; and various lifestyle aspects. Diagnostic tools for neurological disorders assist in managing Alzheimer’s by facilitating its early and precise identification using sophisticated imaging methods, biomarker analysis, and cognitive evaluations. As an illustration, data from September 2024, provided by the Australian Institute of Health and Welfare, a government agency located in Australia, indicated that in 2023, roughly 411,100 people in Australia were affected by dementia, with approximately 257,500 being women and 153,700 men. Consequently, the growing incidence of Alzheimer’s disease is fueling the expansion of the neurological disorder diagnostics market.

What Segments Are Included Within The Neurological Disorder Diagnostics Market?

The neurological disorder diagnostics market covered in this report is segmented –

1) By Component: Instruments, Reagents, Kits, Software, Services

2) By Technology: Immunoassay, Polymerase Chain Reaction (PCR) Techniques

3) By Disease Type: Alzheimer’s Disease, Dementia, Parkinson’s Disease, Epilepsy, Traumatic Brain Injury, Other Disease Types

4) By End User: Hospitals And Clinics, Diagnostic Centers, Academic And Research Institutes

Subsegments:

1) By Instruments: Electroencephalography (EEG) Machines, Magnetic Resonance Imaging (MRI) Machines, Computed Tomography (CT) Scanners, Positron Emission Tomography (PET) Scanners, Lumbar Puncture Equipment, Ultrasound Devices, Neurostimulation Devices, Transcranial Magnetic Stimulation (TMS) Devices,

2) By Reagents: Biochemical Reagents, Antibodies, DNA Probes, RNA Probes, Enzyme-linked Immunosorbent Assay (ELISA) Reagents, Polymerase Chain Reaction (PCR) Reagents, Sample Collection Reagents

3) By Kits: Diagnostic Test Kits, Genetic Testing Kits, Biomarker Detection Kits, Immunoassay Kits, Point-of-Care Testing Kits, Screening Kits for Neurological Disorders

4) By Software: Diagnostic Software for Imaging Analysis, Data Management Software, Clinical Decision Support Software, Patient Management Software, Laboratory Information Management Systems (LIMS), Neuroinformatics Software, Telemedicine Software

5) By Services: Diagnostic Testing Services, Consultation Services, Training and Support Services, Maintenance and Repair Services for Equipment, Telehealth Services, Data Analysis Services, Research and Development Services

What Upcoming Trends Are Likely To Define The Future Path Of The Neurological Disorder Diagnostics Market?

Leading firms within the neurological disorder diagnostics market are concentrating on creating novel solutions, including neurological disease quantification software, to cater to the one billion individuals globally impacted by neurological diseases. This software serves as an instrument for assessing and examining brain activity and the advancement of neurological conditions. An example occurred in January 2024, when Quibim, a biotechnology company headquartered in Spain, introduced the QP-Brain, an AI-driven software designed for early-stage neurological disease quantification. QP-Brain from Quibim represents sophisticated neuroimaging analysis software developed to measure changes in brain tissue associated with neurological conditions. Its distinctive capabilities encompass AI-powered automated segmentation and comprehensive volumetric analysis, providing accurate understanding of shifts in brain structure for both clinical and research purposes.

Who Are The Primary Competitors In The Global Neurological Disorder Diagnostics Market?

Major companies operating in the neurological disorder diagnostics market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Medtronic plc, Amgen Inc., Siemens Healthineers AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Otsuka Pharmaceutical Co. Ltd., Boston Scientific Corporation, Neurocrine Biosciences Inc., Neusoft Medical Systems Co.Ltd., Nihon Kohden Corporation, Natus Medical Incorporated, Esaote S.p.A, Canon Medical Systems Corporation, NeuroPace Inc., Lifelines Neuro Company LLC, York Instruments Ltd., Advanced Brain Monitoring Inc., Neurometrix Inc., Croton Healthcare Private Limited, NeuroLogica Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-diagnostics-global-market-report

Which Regions Are Poised For Strategic Growth In The Neurological Disorder Diagnostics Market?

North America was the largest region in the neurological disorder diagnostics market in 2025. The regions covered in the neurological disorder diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Neurological Disorder Diagnostics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19611&type=smp

Browse Through More Reports Similar to the Global Neurological Disorder Diagnostics Market 2026, By The Business Research Company

Neuroscience Antibodies And Assays Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuroscience-antibodies-and-assays-global-market-report

Interventional Neurology Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/interventional-neurology-devices-and-equipment-global-market-report

Neuroprosthetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuroprosthetics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model